Company Name, Ticker, Customers, else..

Valuation Comparisons

Management Effectiveness

Financial Strength

• Quick Ratio

• Working Capital

• LT Debt to Equity

• Debt to Equity

• Leverage Ratio

• Tangible Leverage

• Interest Coverage

• Debt Coverage

• Work. Cap. Per Revenue

Dividend Comparisons

Syros Pharmaceuticals Inc (SYRS)

Other Ticker:

Sector • Healthcare Industry • Major Pharmaceutical Preparations

Industry • Major Pharmaceutical Preparations

Sector • Healthcare

Syros Pharmaceuticals Inc 's Tangible Leverage Ratio

SYRS's quarterly Tangible Leverage Ratio and Total Liabilities, Tangible Equity growth

Select the Comparisons :

None ▼

Select the Ratio:

Tangible Leverage Ratio ▼

None ▼

Tangible Leverage Ratio ▼

SYRS Tangible Leverage Ratio	(Dec 31 2022) IV. Quarter	(Sep 30 2022) III. Quarter	(Jun 30 2022) II. Quarter	(Mar 31 2022) I. Quarter	(Dec 31 2021) IV. Quarter
Y / Y Tangible Equity Change	49.89 %	21.79 %	-76.14 %	-58.14 %	-5.89 %
Y / Y Total Liabilities Change	-26.9 %	-22.6 %	-8.23 %	-19.33 %	-20.36 %
Tangible Leverage Ratio MRQ	0.56	0.61	3.07	1.42	1.15
Overall Ranking	# 926	# 1313	# 0	# 1340	# 1997
Seq. Tangible Equity Change	-1.11 %	316.43 %	-50.56 %	-26.37 %	-19.65 %
Seq. Total Liabilities Change	-9.52 %	-17.09 %	6.58 %	-8.57 %	-4.18 %

New: More SYRS's historic Tangible Leverage Ratio results >>

Comment on SYRS Tangible Leverage Ratio in the forth quarter 2022

Due to repayements of liabilities of -9.52% Syros Pharmaceuticals Inc improved Tangible Leverage Ratio in forth quarter 2022 to 0.56, below the company's average Tangible Leverage Ratio.

Within Major Pharmaceutical Preparations industry in the forth quarter 2022, 205 other companies have achieved lower Tangible Leverage Ratio than Syros Pharmaceuticals Inc in the IV Quarter 2022. While Tangible Leverage Ratio total ranking has improved so far in the forth quarter 2022 to 926, from total ranking in the third quarter 2022 at 1313.

Explain Tangible Leverage Ratio?
What is SYRS Market Share?
What are SYRS´s Total Liabilities?

Tangible Leverage Ratio forth quarter 2022 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 206
Healthcare Sector	# 391
Overall Market	# 926

Tangible Leverage Ratio Statistics
High	Average	Low
3.07	0.75	0.03
(Jun 30 2022)		(Jun 30 2017)

Financial Statements
Syros Pharmaceuticals Inc 's Tangible Equity	$ 128 Millions	Visit SYRS's Balance sheet
Syros Pharmaceuticals Inc 's Total Liabilities	$ 71 Millions	Visit SYRS's Balance sheet
Source of SYRS's Sales		Visit SYRS's Sales by Geography

Cumulative Syros Pharmaceuticals Inc 's Tangible Leverage Ratio

SYRS's Tangible Leverage Ratio for the trailling 12 Months

SYRS Tangible Leverage Ratio	(Dec 31 2022) IV. Quarter	(Sep 30 2022) III. Quarter	(Jun 30 2022) II. Quarter	(Mar 31 2022) I. Quarter	(Dec 31 2021) IV. Quarter
Y / Y Tangible Equity TTM Growth	49.89 %	21.79 %	-76.14 %	-58.14 %	-5.89 %
Y / Y Total Liabilities TTM Growth	-26.9 %	-22.6 %	-8.23 %	-19.33 %	-20.36 %
Tangible Leverage Ratio TTM	0.96	1.17	1.35	1.02	0.88
Total Ranking TTM	# 1272	# 2013	# 2383	# 1874	# 1263
Seq. Tangible Equity TTM Growth	-1.11 %	316.43 %	-50.56 %	-26.37 %	-19.65 %
Seq. Total Liabilities TTM Growth	-9.52 %	-17.09 %	6.58 %	-8.57 %	-4.18 %

SYRS Company Profile >> Back to SYRS Financial Strength Comparisons >> See SYRS Balance Sheets

TTM Tangible Leverage Ratio Comment

On the trailing twelve months basis Due to repayements of liabilities of -9.52% Syros Pharmaceuticals Inc decreased Tangible Leverage Ratio in the 12 months ending in IV Quarter 2022 to 0.96, below the company's average Tangible Leverage Ratio.
Tangible Leverage Ratio is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry 147, during the past 12 months, other companies have achieved lower Tangible Leverage Ratio than Syros Pharmaceuticals Inc . While Tangible Leverage Ratio total ranking has improved so far to 1272, from total ranking in previous 12 month period at 2013.

Explain Tangible Leverage Ratio?
What is SYRS Market Share?
What are SYRS´s Total Liabilities?

TTM Tangible Leverage Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 148
Healthcare Sector	# 335
Within the Market	# 1272

TTM Tangible Leverage Ratio Statistics
High	Average	Low
1.42	0.97	0.34
(Sep 30 2022)		(Jun 30 2019)

Companies with similar Tangible Leverage Ratio in the quarter ending Dec 31 2022, within Major Pharmaceutical Preparations Industry	Tangible Leverage Ratio	Dec 31 2022 MRQ Total Liabilities	Dec 31 2022 MRQ Tangible Equity
Sonoma Pharmaceuticals Inc	1.51	$ 8.369 Millions	$ 5.559 Millions
Eton Pharmaceuticals Inc	1.44	$ 11.952 Millions	$ 8.324 Millions
Acasti Pharma Inc	1.43	$ 20.008 Millions	$ 13.946 Millions
Avid Bioservices Inc	1.43	$ 265.035 Millions	$ 185.395 Millions
Veru Inc	1.43	$ 54.684 Millions	$ 38.260 Millions
Equillium Inc	1.42	$ 45.247 Millions	$ 31.942 Millions
Oncorus Inc	1.41	$ 85.061 Millions	$ 60.525 Millions
Geron Corp	1.38	$ 110.577 Millions	$ 79.998 Millions
Biofrontera Inc	1.30	$ 27.006 Millions	$ 20.846 Millions
Arvinas Inc	1.25	$ 703.900 Millions	$ 564.900 Millions
Immunogen inc	1.24	$ 193.110 Millions	$ 155.826 Millions
Marinus Pharmaceuticals inc	1.24	$ 143.518 Millions	$ 116.000 Millions
Sigilon Therapeutics Inc	1.23	$ 48.136 Millions	$ 39.142 Millions
2seventy Bio Inc	1.19	$ 346.199 Millions	$ 291.108 Millions
Nektar Therapeutics	1.19	$ 343.962 Millions	$ 290.137 Millions
Arcutis Biotherapeutics Inc	1.18	$ 239.693 Millions	$ 202.393 Millions
Royalty Pharma Plc	1.17	$ 11,185.316 Millions	$ 9,525.373 Millions
Lifevantage Corp	1.15	$ 35.937 Millions	$ 31.374 Millions
Harmony Biosciences Holdings inc	1.12	$ 271.032 Millions	$ 241.885 Millions
Ligand Pharmaceuticals Inc	1.11	$ 165.183 Millions	$ 149.357 Millions
Lexicon Pharmaceuticals Inc	1.06	$ 77.175 Millions	$ 72.581 Millions
Eterna Therapeutics Inc	1.01	$ 10.172 Millions	$ 10.063 Millions
Corbus Pharmaceuticals Holdings Inc	1.01	$ 33.322 Millions	$ 32.990 Millions
Macrogenics Inc	0.97	$ 138.455 Millions	$ 142.013 Millions
Verastem inc	0.97	$ 46.189 Millions	$ 47.391 Millions
Roivant Sciences Ltd	0.97	$ 1,247.440 Millions	$ 1,281.033 Millions
Rani Therapeutics Holdings Inc	0.96	$ 71.172 Millions	$ 74.004 Millions
Palatin Technologies Inc	0.96	$ 15.633 Millions	$ 16.344 Millions
Cerevel Therapeutics Holdings Inc	0.95	$ 496.584 Millions	$ 521.238 Millions
Ardelyx Inc	0.93	$ 91.737 Millions	$ 98.329 Millions

Date modified: 2023-03-03T14:50:46+00:00


Economy Advance Monthly Sales Consumer Price Index CPI Producer Price Index PPI Retail Inventories Personal Income Gross Domestic Product GDP Money Supply Industrial Production Productivity Employment Situation US International Trade Factory Orders Durable Goods Construction Spending Housing Starts Vehicle Unit Sales	Stocks Event Calendar AVD's Profile Stock Price AVD's Financials Business Description Fundamentals Charts & Quotes AVD's News Suppliers AVD's Competitors Customers & Markets Economic Indicators AVD's Growth Company Segments	Screening Stock Performance Growth Rates Profitability Valuation Dividend Financial Strength Efficiency Largest Companies Management Effectivness

Help

Sitemap

Advertise

About us

Glossary

Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071